To appraise the clinical and cost effectiveness of tofacitinib within its marketing authorisation for treating moderately to severely active ulcerative colitis.
Status In progress
Process STA pre-2018
ID number 1218

Provisional Schedule

Committee meeting: 1 16 August 2018

Project Team

Project lead Thomas Feist

Email enquiries


Key events during the development of the guidance:

Date Update
09 March 2018 Invitation to participate
09 March 2018 In progress, .
20 September 2017 - 18 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance